RGL-232
/ Shanghai Regenelead Therapies
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability and immunogenicity of RGL-232 in patients with advanced malignant solid tumors carrying KRAS mutations
(ChiCTR)
- P1 | N=32 | Not yet recruiting | Sponsor: Zhejiang Cancer Hospital; Shanghai Ruihongdi Pharmaceutical Co., LTD
New P1 trial • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1